Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.

Trial Details

NCT ID
NCT05338931
Phase
PHASE1 / PHASE2
Sponsor
AbClon
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • B cell non-Hodgkin lymphoma based on WHO classification 2017
  • incompatible with existing standard therapies or have had disease progression, and whose standard therapies do not currently have available standar…
  • The Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
  • adequate hematological, kidney, liver, lung, heart and bone marrow function without blood transfusion within two weeks prior to screening

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →